Skip to content
ISMO

You are reading 1 of 2 free-access articles allowed for 30 days

Clinical perspectives on melanoma

Gathering Around Cancer, virtual meeting, 5-6 November 2020

The Gathering Around Cancer conference also heard from Dr Fergal Kelleher, Consultant Oncologist at St James’s Hospital in Dublin, who delivered a talk titled ‘Melanoma update’. Dr Kelleher provided an overview of some trial data from a number of studies and said that it is often the case in trials that there are an insufficient number of events to perform an overall analysis. However, one five-year study on patients with resected stage 3 melanoma, the COMBI-i trial, showed that 12 months of adjuvant therapy dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastases than placebo, with no apparent longterm toxic effects.

Dr Kelleher also reported on the CheckMate 238 phase 3 trial, which showed a 1:1 ratio of treatment with adjuvant nivolumab vs adjuvant dupilumab and demonstrated improvement in survival for nivolumab vs dupilumab, as well as an improvement in distant metastases-free survival for nivolumab. Only 211 of the anticipated 302 overall survival events were observed at four years, said Dr Kelleher, with a statistical difference between the treatment groups in terms of survival. He also touched on the KEYNOTE-054 trial, which showed that in five-year median follow-up, adjuvant pembrolizumab prolonged progression-free survival, with a hazard ratio of 0.57 and a highly statistically-significant P value compared to placebo. Dr Kelleher also presented case studies and told the conference: “It’s really important that we have these adjuvant therapies available to us, because melanoma really has a proclivity to disperse widely.”

It’s really important that we have these adjuvant therapies available to us, because melanoma really has a proclivity to disperse widely

In the metastatic setting, he said “there has always been a difficulty with the combination of immunotherapy and molecularly-targeted agents in melanoma” due to the potential for severe hepatotoxicity. However, he drew attention to a study on a triplet regimen – the IMspire150 trial – which was published recently in Lancet Oncology. This was the first trial of its kind to demonstrate that it is possible to successfully combine immunotherapy and molecularly-targeted agents for metastatic melanoma or unresectable stage 3 melanoma and is “a real finding and a true advance in the treatment of this disease”

Leave a Comment

You must be logged in to post a comment.

Related on the site

HIQA calls for urgent reform of health information system in Ireland

Oct 26, 2021

Core fee to GPs of €15 confirmed for all quadrivalent flu vaccines – PCRS

Oct 22, 2021

ICGP to implement new training model after successful transfer

Oct 22, 2021

Historic day for Irish general practice as transfer of GP training from HSE to ICGP approved by board

Oct 19, 2021
Scroll To Top